313 related articles for article (PubMed ID: 30861182)
1. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Bayaraa B; Imafuku S
J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
[TBL] [Abstract][Full Text] [Related]
2. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
3. Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.
Tokuyama M; Ota M; Saitoh R; Sawamura M; Okitsu N; Shimizu T; Kondoh A; Yamaoka H; Mabuchi T
Tokai J Exp Clin Med; 2020 Dec; 45(4):230-235. PubMed ID: 33300595
[TBL] [Abstract][Full Text] [Related]
4. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
5. Switching biologics in children with psoriasis: Results from the BiPe cohort.
Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
[TBL] [Abstract][Full Text] [Related]
6. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
7. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
Akdogan N; Dogan S; Bostan E; Gulseren D; Yalici-Armagan B; Elcin G; Evans SE; Karaduman A; Atakan N
Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1535-1541. PubMed ID: 34519227
[TBL] [Abstract][Full Text] [Related]
8. Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Yanase T; Tsuruta N; Yamaguchi K; Ohata C; Ohyama B; Katayama E; Sugita K; Kuwashiro M; Hashimoto A; Yonekura K; Higashi Y; Murota H; Koike Y; Matsuzaka Y; Kikuchi S; Hatano Y; Saito K; Takahashi K; Miyagi T; Kaneko S; Ota M; Harada K; Morizane S; Ikeda K; Furue M; Nakahara T; Okazaki F; Sasaki N; Okada E; Yoshida Y; Ito K; Imafuku S
J Dermatol; 2023 Jun; 50(6):753-765. PubMed ID: 36786158
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
11. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience.
Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS
Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339
[TBL] [Abstract][Full Text] [Related]
12. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
13. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
14. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
16. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
[TBL] [Abstract][Full Text] [Related]
17. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
Asahina A; Umezawa Y; Yanaba K; Nakagawa H
J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
[TBL] [Abstract][Full Text] [Related]
18. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
Muramatsu S; Kubo R; Nishida E; Morita A
Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]